You asked:
1. Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:
2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive, please indicate the number treated with the following therapies.
If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:
Cisplatin (mono or combination therapy)
Carboplatin (mono or combination therapy)
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:
